Selective Elimination of Breast Surgery for Invasive Breast Cancer
Omitting breast surgery after neoadjuvant systemic therapy can be feasible, with a 0% ipsilateral breast tumor recurrence rate observed over a median follow‑up of 55.4 months.
In a single‑arm, prospective phase 2 nonrandomized trial of 50 women with cT1‑2N0‑1M0 ERBB2‑positive or triple‑negative invasive breast cancer who achieved residual breast lesions <2 cm after neoadjuvant systemic therapy, omission of breast surgery and target axillary dissection was accompanied by a 0% ipsilateral breast tumor recurrence rate at a median follow‑up of 55.4 months, with 100% disease‑free and overall survival.
Neoadjuvant systemic therapy achieves pathologic complete response in up to 60% of breast cancers. The finding that breast surgery can be avoided in selected patients challenges a longstanding surgical standard and may reduce morbidity without compromising oncologic outcomes.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC